Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2024-200587

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Martine Bagot, Youn H. Kim, Pablo L. Ortiz-Romero, Pier Luigi Zinzani, Neha Mehta-Shah, Olivier Dereure, Marie Beylot-Barry, Stéphane Dalle, Eric D Jacobsen, Auris Huen, Andrea Combalia, Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Michael S. Khodadoust, Julien Viotti, Christine Paiva, Marianna Muller, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 3760–3761.

https://doi.org/10.1182/blood-2022-160239

Published: 2022

Journal Articles

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Blood (2022) 140 (5): 419–437.

https://doi.org/10.1182/blood.2021012057

Published: 2022

Journal Articles

Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome

Gabrielle Sonigo, Alizée Bozonnat, Maëlle Dumont, Nicolas Thonnart, Caroline Ram-Wolff, Adèle de Masson, Martine Bagot, Armand Bensussan, Anne Marie-Cardine

Blood (2022) 139 (17): 2712–2716.

https://doi.org/10.1182/blood.2021014782

Published: 2022

Includes: Supplemental data

Journal Articles

Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients

Adèle de Masson, Delphine Darbord, Gabor Dobos, Marie Boisson, Marie Roelens, Caroline Ram-Wolff, Charles Cassius, Hélène Le Buanec, Pierre de la Grange, Fanélie Jouenne, Baptiste Louveau, Aurélie Sadoux, Jean-David Bouaziz, Anne Marie-Cardine, Martine Bagot, Hélène Moins-Teisserenc, Samia Mourah, Maxime Battistella

Blood (2022) 139 (12): 1820–1832.

https://doi.org/10.1182/blood.2021013341

Published: 2022

Journal Articles

Clinical, pathological, and molecular features of myelodysplasia cutis

Jérémie Delaleu, Rathana Kim, Lin-Pierre Zhao, Adèle de Masson, Marie-Dominique Vignon-Pennamen, Charles Cassius, Caroline Ram-Wolff, Martine Bagot, Emmanuelle Clappier, Lionel Adès, Marie Sebert, Jean-David Bouaziz, Pierre Fenaux, Maxime Battistella

Blood (2022) 139 (8): 1251–1253.

https://doi.org/10.1182/blood.2021013967

Published: 2022

Includes: Supplemental data

Journal Articles

Chimerized Anti-ICOS 314.8 Monoclonal Antibodies Inhibit Tumor Cells and Regulatory T Cells in Patients with Sézary Syndrome

Florent Amatore, Mathilde Barré, Florence Orlanducci, Marc Lopez, Remy Castellano, Caroline Ram-Wolff, Laurent Gorvel, Armelle Goubard, Caroline Gaudy-Marqueste, Martine Bagot, Armand Bensussan, Emmanuel Delaporte, Daniel Olive

Blood (2021) 138 (Supplement 1): 2260.

https://doi.org/10.1182/blood-2021-153345

Published: 2021

Journal Articles

ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells

Florent Amatore, Nicolas Ortonne, Marc Lopez, Mathilde Barré, Florence Orlanducci, Remy Castellano, Saskia Ingen-Housz-Oro, Amandine De Croos, Laurent Gorvel, Armelle Goubard, Reda Bouabdallah, Jean Marc Schiano De Colella, Jean-Jacques Grob, Philippe Gaulard, Martine Bagot, Armand Bensussan, Emmanuel Delaporte, Daniel Olive

Blood (2021) 138 (Supplement 1): 790.

https://doi.org/10.1182/blood-2021-150677

Published: 2021

Journal Articles

Patient Characteristics of Long-Term Responders to Mogamulizumab: Results from the MAVORIC Study

Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Adele de Masson, MD PhD, Hélène Moins-Teisserenc, Takahiro Ito, MSc, Karen Dwyer, BA, Fiona Herr, PhD, Martine Bagot, MD PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141379

Published: 2020

Journal Articles

Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial

Amy C.M. Musiek, MD, Sean Whittaker, MD, Steven M. Horwitz, MD, Martine Bagot, MD PhD, Auris Huen, MD PharmD, David C. Fisher, MD, Paul Haun, MD MSc, Maarten H. Vermeer, MD PhD, Takahiro Ito, MSc, Karen Dwyer, BA, Fiona Herr, PhD, Youn H. Kim, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-141041

Published: 2020

Journal Articles

Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema

Blood (2020) 135 (14): 1101–1110.

https://doi.org/10.1182/blood.2019002300

Published: 2020

Includes: Supplemental data

Journal Articles

HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma

Gabrielle Sonigo, Maxime Battistella, Marie Beylot-Barry, Saskia Ingen-Housz-Oro, Nathalie Franck, Stéphane Barete, Serge Boulinguez, Olivier Dereure, Nathalie Bonnet, Gérard Socié, Pauline Brice, Olivia Boccara, Christine Bodemer, Henri Adamski, Michel D’Incan, Nicolas Ortonne, Sylvie Fraitag, Florence Brunet-Possenti, Stephane Dalle, Felipe Suarez, Ambroise Marçais, François Skowron, Dima Haidar, Eve Maubec, Gerome Bohelay, Liliane Laroche, Antoine Mahé, Elodie Birckel, Jean-David Bouaziz, Isabelle Brocheriou, Romain Dubois, Sarah Faiz, Jehane Fadlallah, Caroline Ram-Wolff, Agnes Carlotti, Guido Bens, Brigitte Balme, Beatrice Vergier, Sara Laurent-Roussel, Lydia Deschamps, Olivier Carpentier, Philippe Moguelet, Genevieve Herve, François Comoz, François Le Gall, Guy Leverger, Antoine Finon, Olivier Augereau, Claire Bléchet, Remy Kerdraon, Laurence Lamant, Emilie Tournier, Frédéric Franck, Valérie Costes-Martineau, Vanessa Szablewski, Sebastien Taix, Isabelle Beschet, Frédéric Guerin, Fernando E. Sepulveda, Martine Bagot, Genevieve de Saint Basile, David Michonneau, Adele de Masson

Blood (2020) 135 (13): 1058–1061.

https://doi.org/10.1182/blood.2019003811

Published: 2020

Includes: Supplemental data

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Martine Bagot, MD PhD, Timothy Illidge, MD PhD, Nicola Pimpinelli, MD, Mehul Dalal, PhD, Athanasios Zomas, Chalid Assaf, MD, Nathalie Waser, PhD, Zhouqin He, MSc, Tina Li, MPH, Robert Sambrook, MSc, Fabrizio Trinchese, Meredith Little, Nawal Bent-Ennakhil, Pablo L. Ortiz-Romero, MD PhD

Blood (2019) 134 (Supplement_1): 5879.

https://doi.org/10.1182/blood-2019-126246

Published: 2019

Journal Articles

Long-Term Clinical Benefit to Anti-CCR4 Mogamulizumab: Results from the Phase 3 Mavoric Study in Previously Treated Cutaneous T-Cell Lymphoma (CTCL)

Martine Bagot, MD PhD, Stéphane Dalle, MD PhD, Lubomir Sokol, MD PhD, Athanasios Tsianakas, MD, Amy Musiek, MD, Pablo Ortiz-Romero, MD, Brian Poligone, MD PhD, Madeleine Duvic, MD, Craig Elmets, MD, Mollie Leoni, MD, Karen Dwyer, Wei Sun, PhD, Elena Nikonova, MD, Youn H. Kim, MD

Blood (2018) 132 (Supplement 1): 2901.

https://doi.org/10.1182/blood-2018-99-118473

Published: 2018

Journal Articles

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Blood (2018) 132 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2018-99-118204

Published: 2018

Journal Articles

Donor Lymphocyte Infusion for Primary Cutaneous T Cell Lymphomas: A Study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the French Study Group on Cutaneous Lymphomas (GFLEC)

Blood (2018) 132 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2018-99-119566

Published: 2018

NARROW

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome

Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients

Clinical, pathological, and molecular features of myelodysplasia cutis

Chimerized Anti-ICOS 314.8 Monoclonal Antibodies Inhibit Tumor Cells and Regulatory T Cells in Patients with Sézary Syndrome

ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells

Patient Characteristics of Long-Term Responders to Mogamulizumab: Results from the MAVORIC Study

Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial

Plasma cell–directed therapies in monoclonal gammopathy–associated scleromyxedema

HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Long-Term Clinical Benefit to Anti-CCR4 Mogamulizumab: Results from the Phase 3 Mavoric Study in Previously Treated Cutaneous T-Cell Lymphoma (CTCL)

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Donor Lymphocyte Infusion for Primary Cutaneous T Cell Lymphomas: A Study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the French Study Group on Cutaneous Lymphomas (GFLEC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only